Search

everythinglearnresearchcommunity

for

Search:↓

Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.

EGFR inhibitors for lung cancer can cause severe skin issues.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Chemotherapy can cause various skin problems, and recognizing them helps improve patient care.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

Topical immunotherapy can treat alopecia areata, but its effectiveness varies and the exact mechanism is unclear.

Nanotechnology can improve tissue healing by controlling immune responses.

Some new drugs show potential for treating blood cancers but have serious side effects and need more research.

Increased pigmentation may protect skin from UVB, new targets for skin disease treatments were identified, sunscreen ingredients don't affect hormones, TNF-α inhibitors may help diabetic wounds, and certain treatments could prevent chemotherapy-induced hair loss.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Microneedle arrays with nanotechnology show promise for painless drug delivery through the skin but need more research on safety and effectiveness.

COVID-19 may cause early hair loss similar to classic temporary hair loss, with further research needed.

Japan improved its regulation of regenerative medicine to ensure safety and prevent unproven treatments.

CNGA3, GLUD1, and SIRT1 are promising targets for treating aging and glioblastoma.

The document concludes that more research is needed to understand and treat Beard Alopecia Areata due to limited current knowledge and evidence.

Superficial cryotherapy is effective and safe for treating alopecia areata, with better results when used early and frequently.

Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.

PRP did not significantly regrow hair in alopecia areata totalis patients.

The document suggests a need for collaboration, better evidence, and a responsible framework to safely and effectively advance regenerative therapies to clinical use.

New protein changes may be involved in the immune attack on hair follicles in alopecia areata.

Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.

An emollient PLUS balm with ADE-G1 significantly improved skin dryness and quality of life in cancer patients with xerosis.

Hair transplantation can successfully treat stubborn alopecia areata.

Clinicians should recognize taste disorders and hair loss as important symptoms in myasthenia gravis patients.